Latest News and Press Releases

Longeveron® completes enrollment of pivotal Phase 2b clinical trial evaluating laromestrocel as a treatment for Hypoplastic Left Heart Syndrome (HLHS).

BPM31510 provides encouraging evidence of the potential for transformative benefit for a disease with high unmet need, supporting further development.The Company plans to seek guidance in Q3 2025 from...

Longeveron issues letter to shareholders highlighting corporate strategy, recent progress and 2025 key priorities and goals.

WHO approved generic name laromestrocel for stem cell therapy Lomecel-B, being developed as potential treatment for Alzheimer's disease and HLHS.

Longeveron reports positive long-term transplant-free survival (100% survival) data from a multi-year study in Hypoplastic Left Heart Syndrome (HLHS)

New York, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) proudly announces that its groundbreaking MDA Kickstart program has received both an FDA Rare Pediatric Disease...

New York, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today a new research program called MDA Kickstart for Ultra-Rare Neuromuscular Disease. The MDA...

Longeveron announces positive Type C meeting with FDA, clarifying regulatory pathway to BLA submission for Lomecel-B for hypoplastic left heart syndrome.

Longeveron reports Q2 2024 financial results and provides business update. Phase 2b clinical trial in HLHS achieves 70% enrollment.

Investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for HLHS.